deus medical semaglutide Diabetes Drug Could Help Reduce Risk for Cardiovascular Events, Study Finds Novo Nordisk to protect US
Description
What are your thoughtsdo you think this will lead to stricter regulation or change in pharma practices
In recent years, new drugs for the treatment of type 2 diabetes (T2D) have been proposed, including glucagon-like peptide 1 (GLP-1) agonists or sodiumglucose cotransporter 2 (SGLT2) inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors
Last week, Eli Lilly and Company launched oral GLP-1 drug across US through Lilly Direct, telehealth providers
It is provided in lyophilized powder form
Rush Medical Group Dr
Do not press the dose button yet
